{"id":22852,"date":"2023-01-16T22:04:00","date_gmt":"2023-01-16T14:04:00","guid":{"rendered":"https:\/\/flcube.com\/?p=22852"},"modified":"2025-01-24T22:08:47","modified_gmt":"2025-01-24T14:08:47","slug":"base-therapeutics-secures-series-a1-funding-to-advance-gene-editing-pipelines","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22852","title":{"rendered":"Base Therapeutics Secures Series A1 Funding to Advance Gene Editing Pipelines"},"content":{"rendered":"\n<p>Base Therapeutics, a Guangdong-based firm specializing in base editing and prime editing technologies, has reportedly raised \u201ctens of millions\u201d of US dollars in a Series A1 financing round. The funding was led by Great Eagle VC, with participation from Baidu Venture, Sincere Capital, GDHT Capital, SPARK VC, and existing investor Highlight Capital. The proceeds will be used to advance multiple base editing pipelines into the Investigational New Drug (IND) filing and clinical trial stages.<\/p>\n\n\n\n<p><strong>Platform and Pipeline Development<\/strong><br>Founded in 2021, Base Therapeutics has quickly established itself as a leader in the gene editing space, boasting a portfolio of nearly 200 base editing tools. The company&#8217;s core product features \u201czero off-target\u201d effects, high targeting editing efficiency, and a small size, making it highly suitable for therapeutic applications. Base Therapeutics is currently developing off-the-shelf natural killer (NK) cell therapies and in vivo gene editing therapies, while also optimizing and developing new gene editing technologies.<\/p>\n\n\n\n<p><strong>Market and Future Outlook<\/strong><br>The successful completion of the Series A1 financing round underscores Base Therapeutics&#8217; potential to drive innovation in gene editing and gene therapy. With strong financial backing and a robust pipeline, the company is well-positioned to advance its base editing programs towards clinical validation. The development of off-the-shelf NK cell therapies and in vivo gene editing treatments could address significant unmet needs in the field of genetic medicine, positioning Base Therapeutics as a key player in the global gene editing market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Base Therapeutics, a Guangdong-based firm specializing in base editing and prime editing technologies, has reportedly&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2334,20,66],"class_list":["post-22852","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-base-therapeutics","tag-finance","tag-gene-therapy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Base Therapeutics Secures Series A1 Funding to Advance Gene Editing Pipelines - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Base Therapeutics, a Guangdong-based firm specializing in base editing and prime editing technologies, has reportedly raised \u201ctens of millions\u201d of US dollars in a Series A1 financing round. The funding was led by Great Eagle VC, with participation from Baidu Venture, Sincere Capital, GDHT Capital, SPARK VC, and existing investor Highlight Capital. The proceeds will be used to advance multiple base editing pipelines into the Investigational New Drug (IND) filing and clinical trial stages.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22852\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Base Therapeutics Secures Series A1 Funding to Advance Gene Editing Pipelines\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22852\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-16T14:04:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-24T14:08:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22852#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22852\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Base Therapeutics Secures Series A1 Funding to Advance Gene Editing Pipelines\",\"datePublished\":\"2023-01-16T14:04:00+00:00\",\"dateModified\":\"2025-01-24T14:08:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22852\"},\"wordCount\":251,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Base Therapeutics\",\"Finance\",\"Gene therapy\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22852#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22852\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22852\",\"name\":\"Base Therapeutics Secures Series A1 Funding to Advance Gene Editing Pipelines - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-01-16T14:04:00+00:00\",\"dateModified\":\"2025-01-24T14:08:47+00:00\",\"description\":\"Base Therapeutics, a Guangdong-based firm specializing in base editing and prime editing technologies, has reportedly raised \u201ctens of millions\u201d of US dollars in a Series A1 financing round. The funding was led by Great Eagle VC, with participation from Baidu Venture, Sincere Capital, GDHT Capital, SPARK VC, and existing investor Highlight Capital. The proceeds will be used to advance multiple base editing pipelines into the Investigational New Drug (IND) filing and clinical trial stages.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22852#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22852\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22852#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Base Therapeutics Secures Series A1 Funding to Advance Gene Editing Pipelines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Base Therapeutics Secures Series A1 Funding to Advance Gene Editing Pipelines - Insight, China&#039;s Pharmaceutical Industry","description":"Base Therapeutics, a Guangdong-based firm specializing in base editing and prime editing technologies, has reportedly raised \u201ctens of millions\u201d of US dollars in a Series A1 financing round. The funding was led by Great Eagle VC, with participation from Baidu Venture, Sincere Capital, GDHT Capital, SPARK VC, and existing investor Highlight Capital. The proceeds will be used to advance multiple base editing pipelines into the Investigational New Drug (IND) filing and clinical trial stages.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22852","og_locale":"en_US","og_type":"article","og_title":"Base Therapeutics Secures Series A1 Funding to Advance Gene Editing Pipelines","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=22852","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-01-16T14:04:00+00:00","article_modified_time":"2025-01-24T14:08:47+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22852#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22852"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Base Therapeutics Secures Series A1 Funding to Advance Gene Editing Pipelines","datePublished":"2023-01-16T14:04:00+00:00","dateModified":"2025-01-24T14:08:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22852"},"wordCount":251,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Base Therapeutics","Finance","Gene therapy"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22852#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22852","url":"https:\/\/flcube.com\/?p=22852","name":"Base Therapeutics Secures Series A1 Funding to Advance Gene Editing Pipelines - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-01-16T14:04:00+00:00","dateModified":"2025-01-24T14:08:47+00:00","description":"Base Therapeutics, a Guangdong-based firm specializing in base editing and prime editing technologies, has reportedly raised \u201ctens of millions\u201d of US dollars in a Series A1 financing round. The funding was led by Great Eagle VC, with participation from Baidu Venture, Sincere Capital, GDHT Capital, SPARK VC, and existing investor Highlight Capital. The proceeds will be used to advance multiple base editing pipelines into the Investigational New Drug (IND) filing and clinical trial stages.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22852#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22852"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22852#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Base Therapeutics Secures Series A1 Funding to Advance Gene Editing Pipelines"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22852"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22852\/revisions"}],"predecessor-version":[{"id":22854,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22852\/revisions\/22854"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}